Olive AI's $4B automation bet: $900M raised, units sold off, gone by 2023

Healthcare administrative automation: AI 'digital workers' handling revenue-cycle tasks like prior authorization, claims and utilization management, sold to payers and providers.

That insurers would pay a startup to automate admin workflows — prior auth, claims, utilization review — an 'AI workforce' sold like software at margin.

Sean Lane founded Olive in Columbus, Ohio in 2012, aiming an 'AI workforce' at healthcare's administrative backlog: prior authorization, claims and utilization management were the first targets, sold to payers and hospital groups.

Funding scaled fast: over $900M raised, reaching a $4B valuation by mid-2021, with deployment at 900+ hospitals in 40 states. But 2022 brought layoffs and retreat from payer-facing expansion, and 2023 became a staged fire sale — Availity took utilization management (April), BurstIQ took business intelligence (June), then Waystar took clearinghouse and patient access and Humata Health took prior authorization in October.

On Oct 31, 2023 Olive announced it was shutting down after selling its remaining business units; Axios broke the news that morning. The company that raised $900M+ at a $4B valuation ended with no standalone entity, its assets and teams dispersed across four buyers.

Payer-admin automation sells through long pilot cycles: insurers evaluate forever, and a startup burning a $4B valuation needs customers faster than health plans commit.

Olive marketed an 'AI workforce' at marquee prices before the platform had durable proof; when hospitals pushed on ROI, expansion bets had no recurring revenue behind them.

The 2021 peak priced Olive into a category it never owned — payment integrity had entrenched incumbents — so when money froze, no cheaper capital could bridge to profit.

The staged 2023 divestitures preserved value for creditors and kept the software alive inside buyers, but made closure inevitable rather than a turnaround.

Vision priced at a $4B valuation needs revenue that compounds at that pace. Olive sold automation for healthcare's worst paperwork, but payer sales cycles — not engineering — were the real constraint.

Olive's units survived inside its four buyers: Waystar (clearinghouse, patient access) went public in June 2024, Humata Health and Availity kept the prior-auth and utilization products running, and BurstIQ absorbed the business-intelligence platform. Olive's founder launched a new Columbus startup in January 2024. Ohio's JobsOhio later dropped a lawsuit against the defunct company in December 2024. The collapse became a standard cautionary tale of the 2021 health-tech funding boom — a $4B vision that outran paying demand.